Seroreactivity to a large panel of field-derived Plasmodium falciparum apical membrane antigen 1 and merozoite surface protein 1 variants reflects seasonal and lifetime acquired responses to malaria.

Journal Article

Parasite antigen diversity poses an obstacle to developing an effective malaria vaccine. A protein microarray containing Plasmodium falciparum apical membrane antigen 1 (AMA1, n = 57) and merozoite surface protein 1 19-kD (MSP119, n = 10) variants prevalent at a malaria vaccine testing site in Bandiagara, Mali, was used to assess changes in seroreactivity caused by seasonal and lifetime exposure to malaria. Malian adults had significantly higher magnitude and breadth of seroreactivity to variants of both antigens than did Malian children. Seroreactivity increased over the course of the malaria season in children and adults, but the difference was more dramatic in children. These results help to validate diversity-covering protein microarrays as a promising tool for measuring the breadth of antibody responses to highly variant proteins, and demonstrate the potential of this new tool to help guide the development of malaria vaccines with strain-transcending efficacy.

Full Text

Duke Authors

Cited Authors

  • Bailey, JA; Pablo, J; Niangaly, A; Travassos, MA; Ouattara, A; Coulibaly, D; Laurens, MB; Takala-Harrison, SL; Lyke, KE; Skinner, J; Berry, AA; Jasinskas, A; Nakajima-Sasaki, R; Kouriba, B; Thera, MA; Felgner, PL; Doumbo, OK; Plowe, CV

Published Date

  • January 2015

Published In

Volume / Issue

  • 92 / 1

Start / End Page

  • 9 - 12

PubMed ID

  • 25294612

Electronic International Standard Serial Number (EISSN)

  • 1476-1645

International Standard Serial Number (ISSN)

  • 0002-9637

Digital Object Identifier (DOI)

  • 10.4269/ajtmh.14-0140


  • eng